Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Clinical Research in Southampton
Southampton Children's Hospital
A
A
A
Text only
| Accessibility | Privacy and cookies
"Helpful, informative, polite and friendly staff put my mind at ease"
Patient feedback
Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us
You are here:
Home
>
Search results
Search
Browse site A to Z
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Search results
Go To Advanced Search
Search
You could also try:
indicative (22)
,
suggestive (83)
Vinflunine
Description
Chemotherapy Protocol BLADDER Regimen VINFLUNINE • Bladder – Vinflunine Indication • Bladder cancer that has failed to respond or progressed with in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Vinflunine.pdf
Temsirolimus v1.1
Description
Chemotherapy Protocol RENAL CELL TEMSIROLIMUS This protocol may require funding Regimen Renal Cell - Temsirolimus Indication First line treatmen
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Temsirolimus-v1.1.pdf
Sunitinib v1.1
Description
Regimen Renal Cell - Sunitinib Indication Chemotherapy Protocol RENAL CELL SUNITINIB First line treatment of advanced or metastatic renal cell carcinoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Sunitinib-v1.1.pdf
Pazopanib v1.1
Description
Chemotherapy Protocol RENAL CELL PAZOPANIB Regimen Renal Cell - Pazopanib Indication First line treatment option for people with advanced renal cell carcinoma Second l
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Pazopanib-v1.1.pdf
Lenalidomide Ver 1.1
Description
Chemotherapy Protocol LYMPHOMA LENALIDOMIDE There are multiple versions of this protocol in use. Please ensure you have the correct pr
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-Ver-1.1.pdf
Ibrutinib (MCL) (560mg)
Description
Chemotherapy Protocol Mantle Cell Lymphoma Regimen Ibrutinib • MCL – Ibrutinib (560mg) Indication • Mantle Cell Lymphoma with cyclin D
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Ibrutinib-MCL-560mg.pdf
FC PO (5 day)-Cyclophosphamide-Fludarabine PO 5 day Ver 1.1
Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-FLUDARABINE ORAL 5 DAY (FC PO 5 day) Regimen Lymphoma – FC PO (5 day)-Cyclophosphamide
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-PO-5-day-Cyclophosphamide-Fludarabine-PO-5-day-Ver-1.1.pdf
Cyclophosphamide-Etoposide PO Ver 1.1
Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE ORAL Regimen Lymphoma – Cyclophosphamide-Etoposide PO Indication Palliative
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Etoposide-PO-Ver-1.1.pdf
CVP-Cyclophosphamide-Prednisolone-Vincristine Ver 1.2
Description
Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-PREDNISOLONE-VINCRISTINE (CVP) Regimen Lymphoma – CVP-Cyclophosphamide-Prednisolone-Vi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/CVP-Cyclophosphamide-Prednisolone-Vincristine-Ver-1.2.pdf
Bexarotene
Description
Chemotherapy Protocol Cutaneous T-cell Lymphoma BEXAROTENE Regimen • Cutaneous T-cell Lymphoma - Bexarotene Indication • Bexarotene is indicated for t
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bexarotene.pdf
231
to
240
of
527
Previous
…
22
23
24
25
26
…
Next
Site policies
Report a problem with this page
Privacy and cookies
Site map
Translation
Last updated: 14 September 2019
Contact details
University Hospital Southampton NHS Foundation Trust
Tremona Road
Southampton
Hampshire
SO16 6YD
Telephone: 023 8077 7222
Useful links
Home
Getting here
What to do in an emergency
Research
Working here
Education
© 2014 University Hospital Southampton NHS Foundation Trust
Browser does not support script.
Browser does not support script.